|
Type |
publikáció |
| 300 |
Napló |
Trissel LA, Gilbert DL, Martinez JF.
Compatibility of propofol injectable emulsion with selected drugs during simulated Y-site administration.
Am J Health-Syst Pharm 1997 ; 54: 1287-1292. |
| 301 |
Napló |
Trissel LA, Gilbert DL, Martinez JF, Baker MB, Walter WV, Mirtallo JM.
Compatibility of parenteral nutrient solutions with selected drugs during simulated Y-site administration.
Am J Health-Syst Pharm 1997 ; 54: 1295-1300. |
| 336 |
Napló |
Forman JK, Lachs JR, Souney PF.
Visual compatibility of acyclovir sodium with commonly used intravenous drugs during simulated Y-site injection.
Am J Hosp Pharm 1987 ; 44: 1408-1409. |
| 404 |
Napló |
Forman JK, Souney PF.
Visual compatibility of midazolam hydrochloride with common preoperative injectable medications.
Am J Hosp Pharm 1987 ; 44: 2298-2299. |
| 616 |
Napló |
Jump WG, Plaza VM, Poremba A.
Compatibility of nalbuphine hydrochloride with other preoperative medications.
Am J Hosp Pharm 1982 ; 39: 841-843. |
| 642 |
Napló |
Baumgartner TG, Knudsen AK, Dunn AJ, Kilroy RA.
Norepinephrine stability in saline solutions.
Hosp Pharm 1988 ; 23: 44,49, 59. |
| 660 |
Napló |
Michaels MR, Stauffer GL, Haas DP.
Propofol compatibility with other intravenous drug products - Two new methods of evaluating IV emulsion compatibility.
Ann Pharmacotherapy 1996 ; 30: 228-232. |
| 921 |
Napló |
Trissel LA, Gilbert DL, Martinez JF.
Incompatibility and compatibility of amphotericin B cholesteryl sulfate complex with selected other drugs during simulated Y-site administration.
Hosp Pharm 1998 ; 33: 284-292. |
| 1057 |
Napló |
Cutie MR.
Compatibility of verapamil hydrochloride injection with commonly used additives.
Am J Hosp Pharm 1983 ; 40: 1205-1207. |
| 1203 |
Napló |
Yuhas EM, Lofton FT, Baldinus JG, Mayron D.
Cimetidine hydrochloride compatibility with preoperative medications.
Am J Hosp Pharm 1981 ; 38: 1173-1174. |
| 1415 |
Napló |
Trissel L.A, Gilbert D.L, Martinez J.F, Baker M.B, Walter W.V, Mirtallo J.M.
Compatibility of medications with 3-in-1 parenteral nutrition admixtures.
JPEN 1999 ; 23: 67-74. |
| 1625 |
Napló |
Trissel LA, Saenz C, Williams YW, Ingram D.
Incompatibilities of lansoprazole injection with other drugs during simulated Y-site coadministration.
Int J Pharm Compound 2001 ; 5: 314-321. |
| 1628 |
Napló |
Das Gupta V.
Stability of pentobarbital sodium after reconstitution in 0.9% sodium chloride injection and repackaging in glass and polypropylene syringes.
Int J Pharm Compound 2001 ; 5: 482-484. |
| 1803 |
Napló |
Trissel, LA, Saenz CA, Ogundele OB, Ingram D, Baker MB.
Compatibility of fenoldopam mesylate with other drugs during simulated Y-site administration.
Am J Health-Syst Pharm 2003 ; 60: 80-85. |
| 1925 |
Napló |
Trissel LA , Williams KY, Gilbert DL.
Compatibility screening of linezolid injection during simulated Y-site administration with other drugs and infusion solutions.
J Am Pharm Assoc 2000 ; 40: 515-519. |
| 3379 |
Napló |
Fox L.M, Wilder A.G, Foushee J.A.
Physical compatibility of various drugs with neonatal total parenteral nutrient solution during simulated Y-site administration.
Am J Health-Syst Pharm 2013 ;70:520-524. |
| 3501 |
Laboratórium |
Ketamine hydrochloride (Ketalar®) - Summary of Product Characteristics
Pfizer 2011 |
| 3503 |
Laboratórium |
Fentanyl - Summary of product Characteristics
Hameln Pharmaceuticals 2012 |
| 3525 |
Laboratórium |
Pethidine hydrochloride - Summary of product Characteristics
AMCO Amdipharm Mercury 2012 |
| 3526 |
Laboratórium |
Clindamycin (Dalacin®) - Summary of Product Characteristics
Pharmacia 2010 |
| 3531 |
Laboratórium |
Morphine sulphate 10 mg/mL injection BP – Summary of Product Characteristics
Wockhardt 2014 |
| 3592 |
Laboratórium |
Cimetidine - Résumé des caractéristiques du produit
Sandoz 2008 |
| 3596 |
Laboratórium |
Chlorpromazine (Largactil®) - Summary of Product Characteristics
Sanofi 2014 |
| 3599 |
Laboratórium |
Glycopyrrolate Injection U.S.P. - Summary of Product Characteristics
Amco Amdipharm Mercry 2013 |
| 3631 |
Laboratórium |
Suxamethonium (Suxamethonium Aguettant®) - Résumé des caractéristiques du produit
Aguettant 2016 |
| 3674 |
Laboratórium |
Erythromycin lactobionate - Summary of Product Characteristics
PanPharma 2016 |
| 3676 |
Laboratórium |
Atracurium bésilate (Atracurium Hospira®) - Résumé des caractéristiques du produit
Hospira 2014 |
| 3931 |
Laboratórium |
Trimébutine (Débridat®) - Résumé des caractéristiques du produit
Pfizer Laboratoire 2016 |
| 3932 |
Laboratórium |
Hydroxocobalamine (Cyanokit®) - Résumé des caractéristiques du produit
Serb Laboratoire 2015 |
| 4009 |
Laboratórium |
Droperidol - Résumé des Caractéristiques du Produit
Panpharma 2017 |
| 4303 |
Napló |
Anderson C, MacKay M.
Stability of Fentanyl Citrate, Hydromorphone Hydrochloride, Ketamine Hydrochloride, Midazolam, Morphine Sulfate, and Pentobarbital Sodium in Polypropylene Syringes.
Pharmacy 2015 3, 379-385. |
| 4428 |
Napló |
Rashed S.M, Sweatman T.W, Thoma L, Hovinga C.A, Phelps S.J.
Chemical Compatibility of Depacon® with Medications Frequently Administered by Intravenous Y-Site Delivery in Patients with Epilepsy or Head Trauma.
J Pediatr Pharmacol Ther 2004 ; 9, 2: 126-132. |
| 4700 |
Laboratórium |
Esketamine 25 mg/mL solution for injection/infusion. - Summary of Product Characteristics
AS Kalceks 2022 |
